World's Best Scientists 2026 revealed!
Suzette Delaloge

Suzette Delaloge

D-Index & Metrics

Medicine

D-Index
93
Citations
40170
World Ranking
10737
National Ranking
332

Overview

Suzette Delaloge is affiliated with the Institut Gustave Roussy in France and has a research profile centered on oncology and related biomedical fields. Their work spans a diverse range of topics primarily focused on breast cancer therapies and treatment studies.

Their recent publications include the following significant papers:

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021, Annals of Oncology)
  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer (2021, Annals of Oncology)
  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial (2020, Journal of Clinical Oncology)
  • Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020, Nature Reviews Clinical Oncology)
  • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer (2022, Annals of Oncology)

The frequent co-authorship network of this scientist includes:

  • Barbara Pistilli (44 publications)
  • Florence Dalenc (41 publications)
  • Étienne Brain (38 publications)
  • Jean-Sébastien Frénel (36 publications)
  • Christelle Lévy (35 publications)

Their scholarly work is commonly published in these journals:

  • Annals of Oncology (47 publications)
  • Cancer Research (37 publications)
  • Journal of Clinical Oncology (29 publications)
  • European Journal of Cancer (20 publications)
  • ESMO Open (19 publications)

Their main fields of study encompass:

  • Medicine (436 publications)
  • Biochemistry, Genetics and Molecular Biology (170 publications)

Key subfields include:

  • Oncology (221 publications)
  • Pulmonary and Respiratory Medicine (120 publications)
  • Cancer Research (85 publications)
  • Genetics (51 publications)
  • Molecular Biology (37 publications)

Core topics of research explored by this scientist cover:

  • Advanced Breast Cancer Therapies (192 publications)
  • Breast Cancer Treatment Studies (124 publications)
  • Cancer Treatment and Pharmacology (100 publications)
  • HER2/EGFR in Cancer Research (96 publications)
  • BRCA gene mutations in cancer (70 publications)
  • PARP inhibition in cancer therapy (56 publications)
  • Global Cancer Incidence and Screening (44 publications)

Best Publications

  • Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

    Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Michel Obeid;Michel Obeid;Michel Obeid

  • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu

  • 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

    Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets

  • Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba

  • The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

    Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Alfredo Criollo;Alfredo Criollo;Alfredo Criollo

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    M.E. Robson;N. Tung;P. Conte;S.-A. Im

  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period

    Fabrice Andre;Khemaies Slimane;Thomas Bachelot;Arianne Dunant

  • Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

    M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale

  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial

    Cristina Saura;Mafalda Oliveira;Yin-Hsun Feng;Ming-Shen Dai

  • Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

    Erika Vacchelli;Yuting Ma;Elisa E. Baracco;Antonella Sistigu

  • Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

    Fabrice Andre;Bastien Job;Philippe Dessen;Philippe Dessen;Attila Tordai

  • The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer.

    Fatima Cardoso;Sibylle Loibl;Olivia Pagani;Alessandra Graziottin

  • Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial

    Jean-Yves Pierga;François-Clément Bidard;Claire Mathiot;Etienne Brain

  • Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

    M. V. Dieci;M. C. Mathieu;V. Guarneri;P. Conte

  • Dual-energy contrast-enhanced digital mammography: initial clinical results

    Clarisse Dromain;Fabienne Thibault;Serge Muller;Françoise Rimareix

  • Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

    Roman Rouzier;Lajos Pusztai;Suzette Delaloge;Ana M. Gonzalez-Angulo

  • 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Kevin Kalinsky;William E. Barlow;Julie R. Gralow;Funda Meric-Bernstam

Frequent Co-Authors

Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Jean-Yves Pierga
Jean-Yves Pierga Institute Curie
Stefan Michiels
Stefan Michiels University of Paris-Saclay
Mario Campone
Mario Campone Grenoble Alpes University
Philippe Vielh
Philippe Vielh Institut Gustave Roussy
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Lajos Pusztai
Lajos Pusztai Yale University
Véronique Diéras
Véronique Diéras Institute Curie
Guido Kroemer
Guido Kroemer Université Paris Cité
Bernard Asselain
Bernard Asselain Institute Curie

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional MD and DO programs, there are several online pathways that can help you advance your healthcare career in the USA. Many students and working professionals look for flexibility, accelerated options, and specializations to meet their educational needs.

For nurses aiming for leadership roles, the fastest dnp online program options allow you to earn a Doctor of Nursing Practice degree on an accelerated timeline. If you prefer a less clinical route, consider a dnp program without clinical hours for greater flexibility.

Those just starting in nursing often choose online lpn programs as a quick and accessible entry into the field. If your interest lies in mental health, you might explore psych nurse practitioner programs to specialize in providing psychiatric care.

These online programs can help you upskill efficiently, balance life commitments, and broaden your career opportunities in the rapidly evolving world of healthcare.

Best Scientists Citing Suzette Delaloge

Trending Scientists

Recently Published Articles